Please assess the completion status of the following clinical trial:

Trial Title: Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Must understand and voluntarily sign an informed consent form~* Must be age \> or = to 18 years to 65 years at the time of singing the informed consent form.~* Must be able to adhere to the study visit schedule and other protocol requirements~* Must have a history of severe plaque type psoriasis for at least 6 months, and at least a 15% affected total body surface area (BSA)~* Must meet the following clinical laboratory criteria:~* White Blood Cell Count \> or = to 3000/cu mm and \< 20,000/cu mm~* Platelet count \> or = to 100,000/microliters~* Serum creatinine \< or = to 1.5 mg/dl~* Total bilirubin \< or = to 2.0 mg/dl~* AST (SGOT) and ALT (SGPT) \< or = to 1.5 X ULN~* Must have a psoriatic plaque \> or = to 2.5 cm in diameter (for biopsy)~* Must be candidate for photo/systemic therapy (a subject is considered a candidate for photo/systemic therapy if a clinician judges that the subject requires any systemic therapy (e.g., ultraviolet light B(UVB), Psoralens and long-wave ultraviolet radiation (PUVA), cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine)to control psoriasis whether or not that subject has a history of receiving systemic therapy)~* Women of child bearing potential (WCBP) must have a negative urine pregnancy test at Screening (Visit 1). In addition, sexually active WCBP must agree to use two forms of adequate forms on contraception throughout the trial.~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality , or psychiatric illness that would prevent the subject from signing the informed consent form~* Pregnant or lactating females~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study~* Current erythrodermic, guttate, or pustular psoriasis~* Use of medication that is metabolized by the CYP3A4 or CYP2A6 pathways within the 14 days of study medication initiation and/or required use of such medication during study treatment.~* Drinking or ingesting grapefruits, grapefruit juice or grapefruit containing products within 14 days of study medication initiation~* Use of topical therapy ( topical steroids, topical vitamin A or D analog preparations, tacrolimus, pimecrolimus, or anthralin) within 14 days of study medications initiation (Exception: Non-medicated emollients and tar shampoo will be allowed)~* Use of systemic therapy for psoriasis~* Use or phototherapy within 28 days of study medication initiation~* Use Humira or Remicade within 3 months of study medication initiation~* Use of Enbrel within 56 days of study medication initiation~* Use of Raptiva within 56 days of study medication initiation~* Use of Amevive within 6 months of study medication initiation~* Use of any investigational drug within 30 days of study medication initiation or 5 half lives if known~* History of clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic insufficiency disease or other major diseases~* Clinically significant abnormality on 12-lead ECG at screening~* Positive HIV, Hepatitis B or Hepatitis C laboratory result at screening~* History of active tuberculosis within previous 3 years~* Clinically significant abnormality on the chest x-ray at screening or on CXR taken within 6 months of screening~* History of positive purified protein derivative (PPD) test at screening~* History of malignancy within previous five years~* Evidence of skin conditions at the time of screening visit other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Administration of CC10004 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete